Candel Therapeutics, Inc. (CADL)
After hours:
| Previous close | 12.70 |
| Open | 13.00 |
| Bid | 11.45 x 400 |
| Ask | 11.56 x 400 |
| Day's range | 11.05 - 13.18 |
| 52-week range | 0.66 - 14.30 |
| Volume | |
| Avg. volume | 5,494,295 |
| Market cap | 342.064M |
| Beta (5Y monthly) | -0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.31 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.00 |
GlobeNewswireCandel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024On track for topline disease-free survival data from CAN-2409 phase 3 clinical trial in localized intermediate/high risk prostate cancer, expected in Q4 2024 NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Can
- GlobeNewswire
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing
ZacksCandel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
